靶向TROP-2的抗体药物偶联物在晚期非小细胞肺癌中的研究进展及展望  

Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer

作　　者：许静妍 刘嘉淇 梅世琪 周清 Jingyan XU;Jiaqi LIU;Shiqi MEI;Qing ZHOU(Guangdong Provincial Institute of Lung Cancer,Guangdong Provincial People's Hospital Affiliated to Southern Medical University,Guangdong Academy of Medical Sciences,Guangzhou 510080,China)

机构地区：[1]广东省肺癌研究所,南方医科大学附属广东省人民医院(广东省医学科学院),广州510080

出　　处：《中国肺癌杂志》2024年第10期763-776,共14页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金项目(No.82373349);南方医科大学科技攀峰青年人才培养专项计划项目(No.G623281109)资助。

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)仍是全球范围内的重大健康负担,患者亟待新的治疗选择。人滋养层细胞表面抗原2(trophoblast cell surface antigen-2,TROP-2)作为一种与NSCLC预后密切相关的靶点,已成为近年来的研究热点。其中,靶向TROP-2的抗体药物偶联物(antibody-drug conjugates,ADC)在NSCLC治疗领域取得了突破性进展。临床研究表明,部分TROP-2 ADC药物可显著改善既往经治的晚期/转移性NSCLC患者(无论是否伴有可靶向基因组改变)的无进展生存期,且在后线及一线治疗中均表现出可观的获益潜能。在药物安全性方面,尽管此类药物所引发的血液系统、呼吸系统和消化系统等各系统的不良反应大多可控,但仍需临床密切监测和及时管理。总之,TROP-2 ADC在NSCLC治疗领域具有广阔前景。Non-small cell lung cancer(NSCLC)remains a significant global health burden,and there is an urgent need for new treatment options.Trophoblast cell surface antigen-2(TROP-2),a target closely associated with NSCLC prognosis,has become a research hotspot in recent years.Notably,TROP-2-targeted antibody-drug conjugates(ADCs)have made groundbreaking advances in NSCLC therapy.Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC,regardless of the presence of actionable genomic alterations.These agents have shown promising potential in both frontline and subsequent treatment settings.In terms of safety,while adverse effects affecting the hematologic,respiratory,and gastrointestinal systems are generally manageable,close clinical monitoring and timely management are still required.In conclusion,TROP-2 ADCs hold great promise in the treatment of NSCLC.

关 键 词：肺肿瘤 可靶向基因组改变 抗体药物偶联物 人滋养层细胞表面抗原2 药物治疗 

分 类 号：R734.2[医药卫生—肿瘤]